← Back to Search

Continuous Glucose Monitoring Device

DEXCOM G6 CGM for Diabetic Ketoacidosis

Waitlist Available
Led By Magdalena Bogun, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up up to 20 days
Awards & highlights


This trial is investigating whether the DEXCOM G6 continuous glucose monitor (CGM) can replace traditional hourly fingerstick glucose monitoring for patients with diabetic ketoacidosis (DKA) in the hospital.

Eligible Conditions
  • Diabetic Ketoacidosis


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 20 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 20 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to Resolution of Metabolic Acidosis
Secondary outcome measures
Cost savings
Length of Hospital Stay
Length of ICU Stay
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: DEXCOM G6 CGMExperimental Treatment1 Intervention
Continuous glucose monitoring by DEXCOM G6 (glucose monitoring device) in a step-down unit in participants with DKA
Group II: Hourly Finger Stick Point of Care (Historical Control)Active Control1 Intervention
Retrospective chart review of DKA patients that received hourly glucose monitoring by finger stick while in the ICU

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,448 Previous Clinical Trials
2,531,392 Total Patients Enrolled
DexCom, Inc.Industry Sponsor
138 Previous Clinical Trials
29,719 Total Patients Enrolled
Magdalena Bogun, MDPrincipal InvestigatorColumbia University
~33 spots leftby Jul 2025